Abstract 159P
Background
Obesity is a risk factor for several cancer. In Korea, prevalence of obesity has increased and incidence of several cancers of gastrointestinal (GI) tract, such as colon cancer and rectal cancer have increased. The aim of this study was to evaluate the association between obesity prevalence and cancer incidence of gastrointestinal tract in Korea adults.
Methods
The data were collected from the webpage of Statistic Korea, where the incidence of GI tract cancer between 2001 and 2016 was obtained from National Cancer Center, and the prevalence of obesity between 2001 and 2016 was obtained from National Health and Nutrition Examination Survey. The obesity was defined as BMI ≥25 kg/m2 among adults ≥30 years old. The association between obesity and cancer of GI tract was calculated by using linear regression analysis.
Results
In men, prevalence of obesity was significantly associated with esophageal cancer (β: 0.176, P = 0.001), colon cancer (β: 2.034, P = 0.013), rectal cancer (β: 1.305, P = 0.035), gallbladder cancer and other biliary tract cancer (β: 0.712, P < 0.0001), and pancreatic cancer (β: 0.717, P < 0.0001). But, gastric cancer (β: 1.396, P = 0.076) and liver cancer (β: 0.122, P = 0.496) were not associated with obesity prevalence (Table) In women, incidence of GI tract cancer was not associated with obesity prevalence.Table:
159P Linear regression between obesity and GI cancer in men adults
Cancer | Beta coefficient | 95% CI | P value |
---|---|---|---|
Esophageal cancer | 0.167 | 0.092 - 0.241 | 0.001 |
Gastric cancer | 1.396 | -1.76 - 2.968 | 0.076 |
Colon cancer | 2.034 | 0.535 - 3.533 | 0.013 |
Rectal cancer | 1.305 | 0.114 - 2.495 | 0.035 |
Liver cancer | 0.122 | -0.262 - 0.506 | 0.496 |
Gallbladder and other biliary tract cancer | 0.712 | 0.498 - 0.927 | <0.0001 |
Pancreatic cancer | 0.717 | 0.434 - 0.999 | <0.0001 |
Conclusions
In Korean adults, incidence of some GI tract cancer seems to be associated with obesity prevalence.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
185P - Evaluation of the effect of cholesorption on the concentration of TNF-α in the serum of the blood in tumours of the biliopancreatoduodenal zone
Presenter: Marufjon Salokhiddinov
Session: Poster display session
Resources:
Abstract
186P - Efficacy and safety of sorafenib following hepatic resection in patients with hepatocellular carcinoma: A meta-analysis
Presenter: Yang Yuan
Session: Poster display session
Resources:
Abstract
187P - Correlation between spleenic dose and grade of hematological toxicity in chemoradiation of stomach
Presenter: Umesh Velu
Session: Poster display session
Resources:
Abstract
188P - Survival and prognostic factors in cholangiocarcinoma: A single-center experience
Presenter: Sonngwit Payapwattanawong
Session: Poster display session
Resources:
Abstract
189P - Stereotactic body radiotherapy in primary hepatocellular carcinoma and oligometastatis to liver: A single Institution experience
Presenter: Sayan Paul
Session: Poster display session
Resources:
Abstract
190P - Details of response with first-line gemcitabine and nab-paclitaxel therapy in patients with advanced pancreatic cancer
Presenter: Yusuke Nagata
Session: Poster display session
Resources:
Abstract
191P - Assessment of efficacy and safety of sorafenib versus no treatment in Egyptian hepatocellular carcinoma patients
Presenter: Noha El Baghdady
Session: Poster display session
Resources:
Abstract
192P - Clinical importance of the determination of interleukin-6 in bile and blood in tumours of biliopancreatoduodenal zone
Presenter: Marufjon Salokhiddinov
Session: Poster display session
Resources:
Abstract
193P - Metastatic carcinoma gall bladder: A clinicoepidemiological profile of Indian patients
Presenter: Anvesh Rathore
Session: Poster display session
Resources:
Abstract
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract